Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217071 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Sue Yom.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03217071 is a Phase 2 study that has completed, run by Sue Yom. The registered enrollment target is 12 participants.
The verdict
NCT03217071, a Phase 2 study, has completed, sponsored by Sue Yom.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their lung cancer.
Interventions
- DRUG Pembrolizumab
- RADIATION stereotactic radiation therapy (SRT)
- PROCEDURE Surgery (Non-interventional, standard of care)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217071
The ClinicalTrials.gov registry entry for NCT03217071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sue Yom, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03217071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217071 about?
NCT03217071 is a clinical study titled "Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer". This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their lung cancer.
What is the current status of trial NCT03217071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-10-04. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT03217071?
The interventions under investigation include: Pembrolizumab (DRUG), stereotactic radiation therapy (SRT) (RADIATION), Surgery (Non-interventional, standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT03217071?
This trial is sponsored by Sue Yom, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.